Rate My Professor Marc-Emmanuel Dumas

Professor Marc-Emmanuel Dumas holds the Chair in Systems Medicine at Imperial College London within the Faculty of Medicine's Department of Metabolism, Digestion and Reproduction, where he serves as Head of the Division of Systems Medicine and Head of the Biomolecular Medicine section. He is also a CNRS Director of Research at the European Genomic Institute for Diabetes (EGID) in Lille, France, and Director of the Imperial-University of Lille-CNRS International Research Project in Integrative Metabolism. Dumas earned a PhD in Biochemistry, Molecular and Cell Biology, following studies in agricultural engineering, and holds additional qualifications including MEng, MSc, BEng, and BSc. His career at Imperial College London began with a Wellcome Trust-funded post-doctoral position in 2002, progressing through Lecturer in Systems Biomedicine (2009-2013), Senior Lecturer in Translational Systems Biomedicine (2013-2015), Reader in Translational Systems Medicine (2015-2018), to his current Chair in 2019. Previously, he was a CNRS senior scientist at the École Normale Supérieure de Lyon (2007-2009).

Dumas is a Fellow of the Royal Society of Biology (FRSB) and the Royal Society of Chemistry (FRSC). His research specializes in systems medicine, focusing on metabolomics using 1H NMR spectroscopy and high-resolution mass spectrometry to study metabolite and lipid networks in metabolic and cardiorespiratory diseases, including type 2 diabetes, obesity, ischemic heart disease, and non-alcoholic fatty liver disease. He integrates multi-omics data including metabolomics, metagenomics, and transcriptomics to elucidate host-microbiome interactions and underlying biological mechanisms. Key publications include "A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice" (Nature Medicine, 2017), "Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity" (Gut, 2016), "Impact of the gut microbiota on inflammation, obesity, and metabolic disease" (Genome Medicine, 2016), and "Genetic mechanisms of critical illness in COVID-19" (Nature, 2021). Dumas heads Imperial's Microbiome Network and advances precision medicine through studies of microbiome-derived metabolites like trimethylamine N-oxide and hippurate.